Loading…
Cellectis S.A. is projected to rise to $3.25 by 2027, a +18% move from its current price of $2.75. CLLS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.68 | $2.75 | $2.83 | +0.06% |
| Aug 4 | $2.65 | $2.75 | $2.86 | +0.11% |
| Aug 5 | $2.63 | $2.75 | $2.89 | +0.17% |
| Aug 6 | $2.61 | $2.76 | $2.91 | +0.23% |
| Aug 7 | $2.60 | $2.76 | $2.93 | +0.29% |
| Aug 8 | $2.58 | $2.76 | $2.95 | +0.34% |
| Aug 9 | $2.57 | $2.76 | $2.97 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.57 | $2.76 | $2.97 | +0.40% |
| Week 2 | $2.50 | $2.77 | $3.07 | +0.80% |
| Week 3 | $2.46 | $2.78 | $3.15 | +1.21% |
| Week 4 | $2.42 | $2.79 | $3.23 | +1.61% |
| Week 5 | $2.39 | $2.81 | $3.29 | +2.02% |
| Week 6 | $2.36 | $2.82 | $3.36 | +2.43% |
| Week 7 | $2.34 | $2.83 | $3.42 | +2.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectis S.A. is a clinical stage biotechnological company focused on gene-editing. It develops products based on allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy product candidates in other therapeutic indications.
Its portfolio includes BALLI-01, lasme-cel, to evaluate safety, expansion, persistence, and clinical activities in patients with r/r ALL; NatHaLi-01, designed to evaluate eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC); and Melanoma, for treatment of unresectable or metastatic melanoma.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A. (CLLS) is a healthcare company with a current price of $2.89 and a market cap of $291.02M, ranking 3360 by market capitalization.
The stock’s current price and market positioning place it within a narrow trading range as it progresses through near-term dynamics. The long-term outlook is bullish, with a multi-year forecast showing rising average prices and sizable ROI by 2050, including an average forecast of $19.70 and a max of $38.16 in 2050.
From 2027 onward, the forecast signals a bullish sentiment with increasing average prices and higher max values, culminating in substantial long-term returns. The 2026 figure is neutral with a 0% ROI, while later years show meaningful upside potential.
A major floor 20.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 20.0% above — a clean break opens room to run.
A major ceiling 60.7% above — clearing it would confirm fresh momentum.
Key CLLS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLLS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.84 | Sell | $2.81 | Sell |
| MA 10 | $2.79 | Sell | $2.82 | Sell |
| MA 20 | $2.88 | Sell | $2.86 | Sell |
| MA 50 | $3.05 | Sell | $3.06 | Sell |
| MA 100 | $3.38 | Sell | $3.29 | Sell |
| MA 200 | $3.75 | Sell | $3.35 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.79 | Neutral |
| Stoch RSI (14) | 59.05 | Neutral |
| CCI (20) | -59.80 | Neutral |
| Williams %R (14) | -48.28 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.14 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 51.72 | Neutral |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 42.88 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 2.84 | Sell |
| ADX (14) | 16.22 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL with an RSI(14) of 50.
The stock trades below its short- and long-term moving averages, with SMA50 at $3.16 and SMA200 at $3.79, suggesting near-term softness relative to those benchmarks.
The 30-day range spans $2.36 to $3.54, providing nearby support around $2.60 and resistance around $3.30.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $2.75 | $3.63 | 0% | Neutral | |
| $2.59 | $3.25 | $4.30 | +18% | Neutral | |
| $3.00 | $3.86 | $5.31 | +40% | Bullish | |
| $3.23 | $4.26 | $6.04 | +55% | Bullish | |
| $3.23 | $4.34 | $6.30 | +58% | Bullish | |
| $3.36 | $4.60 | $6.82 | +67% | Bullish | |
| $3.23 | $4.50 | $6.80 | +64% | Bullish | |
| $3.35 | $4.75 | $7.30 | +73% | Bullish | |
| $4.09 | $5.88 | $9.18 | +114% | Bullish | |
| $4.34 | $6.34 | $10.04 | +130% | Bullish | |
| $5.03 | $7.86 | $13.25 | +186% | Bullish | |
| $9.90 | $17.33 | $31.94 | +530% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.60 | $2.75 | $3.28 | +0.00% |
| September 2026 | $2.33 | $2.75 | $3.35 | +0.17% |
| October 2026 | $2.43 | $2.90 | $3.56 | +5.18% |
| November 2026 | $2.48 | $2.97 | $3.68 | +2.36% |
| December 2026 | $2.41 | $2.91 | $3.63 | -2.01% |
Click any year to see its month-by-month CLLS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLLS price prediction for 2026 points to an average of $2.75 (low $2.60, high $3.63) — a potential gain of 0% on today's $2.75. A consolidation phase looks the most probable path here.
In 2027, CLLS is projected to trade between $2.59 and $4.30, averaging $3.25 — a potential gain of +18% from today's $2.75. That is up +18% on the projected 2026 average. Price action looks broadly range-bound.
Cellectis S.A.'s 2028 outlook centres on $3.86, within a $3.00 to $5.31 range. That is up +19% on the projected 2027 average. That marks a +40% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CLLS could reach as high as $6.04, with a base case around $4.26 and support toward $3.23 — roughly +55% from $2.75. Momentum favours further upside here.
Expect CLLS to range from $3.23 to $6.30 through 2030. The $4.34 average target implies a +58% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CLLS price prediction for 2031 points to an average of $4.60 (low $3.36, high $6.82) — a potential gain of +67% on today's $2.75. Momentum favours further upside here.
In 2032, CLLS is projected to trade between $3.23 and $6.80, averaging $4.50 — a potential gain of +64% from today's $2.75. That is -2% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Cellectis S.A.'s 2033 outlook centres on $4.75, within a $3.35 to $7.30 range. That is up +5% on the projected 2032 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2034, CLLS could reach as high as $9.18, with a base case around $5.88 and support toward $4.09 — roughly +114% from $2.75. Buyers look set to stay in control over this stretch.
Expect CLLS to range from $4.34 to $10.04 through 2035. The $6.34 average target implies a +130% move from current prices. That is up +8% on the projected 2034 average. Momentum favours further upside here.
The CLLS price prediction for 2040 points to an average of $7.86 (low $5.03, high $13.25) — a potential gain of +186% on today's $2.75. Buyers look set to stay in control over this stretch.
In 2050, CLLS is projected to trade between $9.90 and $31.94, averaging $17.33 — a potential gain of +530% from today's $2.75. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CLLS today (≈ 363.636364 CLLS) could be worth
$6,301.17
+$5,301.17 (+530%) by 2050 · US Dollar
Based on the average projected CLLS price of $17.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLLSwould be worth at today's price.
$1,000 invested in CLLS on Jul 31, 2025 (≈ 398.406376 CLLS) would be worth
$1,095.62
+$95.62 (+9.6%) today · 1.10× · US Dollar
Based on a CLLS entry price of $2.51 vs. today's $2.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.84 | $968.31 | -3.2% |
| 1 month ago | $2.94 | $935.37 | -6.5% |
| 3 months ago | $3.95 | $696.2 | -30.4% |
| 6 months ago | $3.82 | $719.9 | -28.0% |
| 1 year ago | $2.51 | $1,095.62 | +9.6% |
| All time (5.0y) ago | $13.62 | $201.91 | -79.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLLS forecast.
Our base-case forecast reaches $5.50 around 2034.
Implied market cap at $5.50: $399.84M
The multi-year forecast shows a bullish trajectory beginning in 2027 and extending through 2050. For 2026, the min is $2.60, avg $2.89, max $3.87 with an ROI of 0% and a NEUTRAL sentiment. In 2027, the avg rises to $3.51 (min $2.77, max $4.74) with an ROI of 21.6% and a BULLISH sentiment, followed by steady gains: 2028 avg $4.20 (min $3.20, max $5.90), ROI 45.2%; 2029 avg $4.67 (min $3.46, max $6.77), ROI 61.4%; 2030 avg $4.76 (min $3.45, max $7.09), ROI 64.7%.
The growth continues through 2031–2035, with 2031 avg $4.99, 2032 $4.86, 2033 $5.20, 2034 $6.54, and 2035 $7.05, all labeled BULLISH and with rising max values and ROIs (e.g., 2035 ROI 144.1%). Mature peaks appear in 2040 (avg $8.68, max $15.26, ROI 200.4%) and culminate in 2050 (avg $19.70, max $38.16, ROI 581.5%), all under a BULLISH sentiment.
These figures illustrate a long-term path toward higher prices and returns, but as with any forecast, they are estimates rather than guarantees. The wide ranges between min and max imply notable variability over time.
Tap a question to reveal the answer.
2030 min $3.45, avg $4.76, max $7.09 with ROI 64.7% and a BULLISH sentiment.
The forecast shows a bullish sentiment from 2027 onward with rising avg prices and ROI, including 2050 with avg $19.70, max $38.16 and ROI 581.5%; 2026 is neutral with ROI 0%.
Yes. The 2035 max is $11.59 and the 2040 max is $15.26, with 2050 max at $38.16, indicating potential for prices above $10 in the extended forecast.
Current price is $2.89 and market cap is $291.02M.
2050 forecast shows min $10.44, avg $19.70, max $38.16 with ROI 581.5% and a BULLISH sentiment.
Cellectis S.A. Community Discussion
0Share your Cellectis S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.